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Abstract
A new subtype of autoimmune encephalitis associated with antibodies against
GABAB receptor was recently identiﬁed. Although immune-mediated functional
abnormalities are suggested for the pathogenesis, functional brain imaging such
as perfusion SPECT has not been documented. A 62-year-old woman with anti-
GABAB receptor associated encephalitis underwent 123I-IMP SPECT in the begin-
ning and after methylprednisolone pulse therapy. Three-dimensional stereotactic
surface projection analysis was used to evaluate the cortical distribution of per-
fusion abnormality. The patient presented with clinical features of subacute lim-
bic encephalitis. Antibodies to GABAB receptor were identiﬁed in her serum and
cerebrospinal ﬂuid (CSF), but no tumor was detected. Despite normal magnetic
resonance imaging (MRI) ﬁndings, the ﬁrst SPECT revealed hypoperfusion of the
frontal, parietal and medial temporal lobes, as well as thalamus, and cerebellum.
These areas are known to contain high levels of GABAB receptors. In contrast, the
SPECTrevealedhyperperfusioninthemotorstripandlefttemporallobe,whichare
areasrelatedtosomeofthepatient’ssymptoms,includingseizures,orolingualdysk-
inesia, and Wernicke aphasia. After treatment with pulses of methylprednisolone,
the neuropsychiatric symptoms resolved and the SPECT ﬁndings showed substan-
tial improvement in most of these regions. In conclusion, the ﬁndings suggest that
immunotherapy improved the cortical dysfunction mediated by GABAB receptor
antibodies.
A 62-year-old woman, who has been brieﬂy described in-
cluding the laboratory data as case 11 of the previous case
series (Lancaster et al. 2010), without preceding illness no-
ticed difﬁculty in speech. On day 6, she presented with a
generalized convulsive seizure. Brain MRI revealed no ab-
normalities. On day 12, she had another seizure. During
the following days she developed memory deﬁcit, disorien-
tation, psychosis, and fever of 37–38◦C. She eventually be-
came delirious, and was admitted to our hospital on day 24.
Functions of the cranial nerves, motor and sensory systems
were normal. Cerebellar ataxia and meningeal signs were
not evident. Brain MRI did not reveal focal lesions or ab-
normal gadolinium enhancement. Lumbar puncture yielded
normal pressure, 80 mmH2O ;t o t a lp r o t e i n ,2 2m g / d L ;a n d
glucose, 79 mg/dL accompanied by increased mononuclear
cellcount,20/μL.PCRofCSFwasnegativeforherpessimplex
virus, cytomegalovirus, varicella zoster virus, and Epstein-
Barr virus. Electroencephalography (EEG) revealed diffuse
slowwaves.CTofthechest,abdomen,andpelvisrevealedno
tumors.
Laboratory blood tests revealed increase in the leukocyte
count(11,070/μL)andC-reactiveprotein(CRP,5.11mg/dL).
Tumormarkerswerewithinnormallimits.Viraltitersdidnot
increase between paired sera 2 weeks apart.
AntibodiestoGABABreceptor(R)wereidentiﬁedinserum
and CSF (Lancaster et al. 2010). The titers of the antibodies
were 40 in the serum and 40 in the CSF, deﬁned as the recip-
rocal of the maximal dilution that gave positive immunos-
taining. Autoantibodies to NMDAR, AMPAR, VGKC, Ma2,
HuD, and CRMP5 were not detected. Other tests including
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antinuclear antibodies, rheumatoid factor, and autoantibod-
ies to DNA, SS-A, SS-B, PR3-ANCA, MPO-ANCA, glutamic
acid decarboxylase, thyroid peroxidase, thyroglobulin, thy-
roid stimulating hormone R, Ri, Hu, and Yo were negative.
Methylprednisolone pulse therapy at 1 g/day for 5 days
and phenytoin were administered i.v. starting on day 25. On
days 25 and 30, she had two generalized seizures, after which
she did not developed further seizures. As her consciousness
recovered over a period of 1 week after treatment, and EEG
revealed restored α waves, she developed Wernicke apha-
sia and orolingual dyskinesia manifesting as chewing and
tongue twisting; these unique symptoms of our patient are
not observed among other 14 patients with anti-GABABR
antibody encephalitis (Lancaster et al. 2010). Methylpred-
nisolone pulse therapy for 3 days was repeated on days 32
and 42 followed by oral prednisolone 50 mg/day. The CSF
cell count and CRP levels normalized, following which she
became afebrile and regained normal mental as well as neu-
rologic functions by day 50. She was discharged with pred-
nisolone 30 mg/day on day 62.
Assessment of brain perfusion using interictal 123I-IMP
SPECT was performed on the fourth day (day 28) of the
ﬁrst course of methylprednisolone pulse therapy and after
the three courses of methylprednisolone pulse therapy (day
46) (Fig. 1). Three-dimensional stereotactic surface projec-
tion analysis was used to evaluate the cortical distribution of
perfusion (Minoshima et al. 1995). Normalized brain activ-
ity of our patient was compared with that of normal con-
trols using the pixel-by-pixel Z-score [(control mean value
− patient value)/control SD], which enabled quantitative as-
sessment of the hypoperfused area. SPECT on day 28, while
our patient was suffering from neurologic manifestations,
showed increased uptake in the superior temporal, middle
temporal,andprecentralaswellaspostcentral gyrioftheleft
hemisphere. It also revealed decreased uptake at the anterior
outer surface of the frontal lobe, thalamus, and cerebellum
on both sides, but more marked on the right side. Decreased
uptakewasalsoobservedintheinferiorparietallobule,supra-
marginal,andparahippocampalgyrioftherighthemisphere
as well as the left rectal gyrus. SPECT on day 46, follow-
ing corticosteroid therapy and neurologic recovery, revealed
normal uptake in all regions, except the bilateral cuneus (in-
creased uptake) and the anterior outer surface of bilateral
frontal lobes and bilateral thalamus (decreased uptake).
The patient’s antibody demonstrated extensive reactivity
with neuropil of the thalamus, hippocampus, cerebellum,
Figure 1. Three-dimensional stereotactic surface projection views of perfusion 123I-IMP-SPECT on day 28 and after methylprednisolone pulse therapy
on day 46. Row (A) Qualitative surface views. Row (B) and (C) Pixel-by-pixel Z-score views of functional reduction (B) and increase (C) in our patient
in comparison with normal controls. RT.LAT = Right lateral; LT.LAT = left lateral; SUP = superior; INF = inferior; ANT = anterior; POST = posterior;
RT.MED = right medial; LT.MED = left medial.
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and cerebral cortex of rat brain (Lancaster et al. 2010). This
localization is consistent with the SPECT ﬁndings, such as
decreased uptake in the thalamus, parahippocampus, cere-
bellum, and cortex of the frontal and parietal lobes seen
in our patient. A possible mechanism of regional cerebral
hypoperfusion is neuronal hypofunction induced by inhibi-
tion of GABABR by the patient’s antibody. This hypothesis is
supported by an observation that, in patients with systemic
lupus erythematosus with cognitive dysfunction, the de-
creaseinGABARdensitymeasuredby 123I-IomazenilSPECT
was linked to the decrease in perfusion measured by 99mTc-
ECD SPECT in the cerebral cortex where MRI was normal
(Mathieu et al. 2010). In a patient with adult-onset
Rasmussen’s encephalitis, interictal 99mTc-HMPAO SPECT
demonstrated an extensive area of cortical hypoperfusion
even in the clinically uninvolved contralateral cerebral hemi-
sphere. The cerebral hemisphere appeared normal on MRI,
indicating that SPECT can detect subclinical pathologic
process (Leach et al. 1999). In addition, the hypoperfused
cortical regions were more extensive in our patient when
correlated with her neurological ﬁndings. Because the hy-
poperfused regions showed good agreement with the anti-
GABABR antibody-binding regions (Lancaster et al. 2010),
anti-GABABR antibody may cause local hypoperfusion that
may not be accompanied by neurological symptoms. In con-
trast, the motor area and left temporal lobe, where SPECT
revealed increased uptake in our patient, may be implicated
in convulsive seizures, orolingual dyskinesia, and Wernicke
aphasia.Positronemissiontomography(PET)withﬂumaze-
nil,aspeciﬁcantagonistofthebenzodiazepinebindingsiteof
GABAAR, demonstrated that hypofunction of the inhibitory
GABA system in the cerebral cortex is accompanied by
neurologic manifestations and local hyperperfusion in a pa-
tient with acute aseptic encephalitis (Iseki et al. 2009). A
similar state could be evoked by anti-GABABRa n t i b o d yi n
our patient. Anyway, precise mechanisms of alterations in
cerebral perfusion induced by the anti-GABABRa n t i b o d y
remain to be elucidated by the further researches.
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